Asset Details
Do you wish to reserve the book?
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Do you wish to request the book?
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Revolutionizing NSCLC Treatment: Immunotherapy Strategies for EGFR‐TKIs Resistance
2024
Overview
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) are the standard treatment choice for advanced non‐small cell lung cancer (NSCLC) patients with EGFR mutations. EGFR‐TKIs have made significant progress in the treatment of advanced NSCLC patients, but drug resistance issues still inevitably arise. The mechanism of drug resistance and subsequent treatment has been current research challenge and priority. Immune checkpoint inhibitors (ICIs) are a new choice for late‐stage NSCLC patients without druggable molecular alterations. Currently, several studies have applied ICIs therapy for NSCLC patients with EGFR‐TKIs resistance and explored the potential efficacy of ICIs. This review elaborates on the current status of immunotherapy after EGFR‐TKIs resistance, including ICIs monotherapy, combined with EGFR‐TKIs, chemotherapy, antiangiogenic drugs, and other therapies. EGFR regulates the expression of PD‐L1.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - immunology
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Carcinoma, Non-Small-Cell Lung - therapy
/ Drug Resistance, Neoplasm - genetics
/ epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI)
/ ErbB Receptors - antagonists & inhibitors
/ Humans
/ Immune checkpoint inhibitors
/ Immune Checkpoint Inhibitors - pharmacology
/ Immune Checkpoint Inhibitors - therapeutic use
/ Lung Neoplasms - drug therapy
/ Mutation
/ non‐small cell lung cancer (NSCLC)
/ Protein Kinase Inhibitors - therapeutic use
/ Review
